Amgen (AMGN) opened 2026 with Q1 revenue of US$8.6 billion and basic EPS of US$3.37, setting the tone for how its earnings story is evolving after a year of stronger profitability. Over the past year, the company has seen trailing twelve month revenue move from US$33.4 billion to US$37.2 billion, while trailing EPS rose from US$7.62 to US$14.48, giving investors a clear view of how the earnings base has scaled alongside higher margins.

See our full analysis for Amgen.

With the latest quarter on the table, the next step is to see how these results line up with the key narratives around Amgen's growth, income profile, and risk, and to identify where the numbers may challenge those views.

Margins and EPS Outpace Revenue Growth

• Over the last 12 months, Amgen generated US$37.2b of revenue and US$7.8b of net income, which works out to a 21% net margin and US$14.48 of EPS on a trailing basis.
• What stands out for the bullish view is that one year earnings growth of 31.5% and the 21% margin benchmark are stronger than the modest 2.8% trailing revenue growth, which supports the idea of margin expansion. However, this sits against a five year earnings trend that was roughly flat, so:
  • Bulls pointing to expanding treatments for chronic diseases and a growing late stage pipeline can reference the strong trailing EPS of US$14.48. Yet the long term earnings trend of around 0% per year shows that sustained growth is not yet evident in the multi year record.
  • The consensus narrative expects revenue growth of 2.3% a year and margins rising to 22%, which is close to the current 21% margin. The recent profitability helps that case but does not yet show a clear break from the slower revenue trend.

Over the last year of results, bulls argue that product demand and pipeline potential could extend these higher margins, while the flat five year earnings record keeps the focus on whether this uplift is durable. 🐂 Amgen Bull Case

P/E and DCF Fair Value Send Mixed Signals

• With a trailing P/E of 22.8x at a share price of US$329.82, Amgen sits below a 41.1x peer average but above the 16.3x US biotech industry average, and the stock is also flagged as trading around 49% below a DCF fair value of about US$649.20.
• Critics highlight that even though the DCF fair value is higher than the current share price and the P/E is below peers, the forecast earnings growth rate of 8.8% a year and revenue growth of 2.8% a year are both slower than the broader US market figures cited, so:
  • The bearish narrative that questions paying a premium multiple for slower growth finds some support in the P/E sitting above the biotech industry average. This can indicate investors are already assigning a higher quality or growth expectation compared with the sector overall.
  • At the same time, the DCF fair value of US$649.20 and consensus price target of US$353.43 are both higher than the current US$329.82 share price. Investors weighing the cautious view need to decide how much weight to give to these valuation frameworks versus the slower growth profile.

Skeptics warn that slower forecast growth and an above industry P/E could limit how much support investors place on the DCF fair value gap if fundamentals do not track the more optimistic scenarios. 🐻 Amgen Bear Case

Earnings Strength Versus Debt Coverage Risk

• Amgen pairs a 21% net margin and US$7.8b of trailing net income with a 3.06% dividend yield, while at the same time debt is flagged as not being well covered by operating cash flow over the last 12 months.
• Consensus narrative views this mix as a balance of strengths and pressure points, because:
  • The reliable 3.06% dividend and solid trailing earnings base align with the view that the business can return cash to shareholders, especially with trailing EPS of US$14.48 underpinning those payouts.
  • The major risk around debt coverage, combined with only 2.8% trailing revenue growth, fits with concerns in both the bearish and consensus narratives that higher investment, pricing pressure, and acquisition activity could strain cash generation if revenue growth does not keep pace.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Amgen on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

The mix of stronger margins, slower revenue growth, and debt considerations leaves room for different views. It makes sense to review the figures yourself and decide how you feel about the balance of risks and rewards, starting with these 3 key rewards and 1 important warning sign.

See What Else Is Out There

Amgen's slower 2.8% trailing revenue growth, flat five year earnings trend, and flagged debt coverage risk raise questions about how resilient its financial profile really is.

If those debt and cash flow concerns leave you wanting sturdier balance sheets, use the solid balance sheet and fundamentals stocks screener (45 results) to quickly spot companies that prioritise financial strength and lower funding risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.